Vancomycin in the treatment of inflammatory bowel disease: there is a role beyond Clostridioides difficile infection

Rev Esp Enferm Dig. 2024 Sep;116(9):500-501. doi: 10.17235/reed.2023.9942/2023.

Abstract

The development of new biological agents and small molecules has revolutionized the treatment of Inflammatory Bowel Disease (IBD). However, many patients do not respond or gradually lose their response, necessitating the search for other therapeutic strategies (1). In this clinical case, we describe the evolution of a patient with difficult-to-manage Crohn's Disease (CD) who was treated with oral vancomycin.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Anti-Bacterial Agents* / therapeutic use
  • Clostridioides difficile
  • Clostridium Infections* / drug therapy
  • Crohn Disease* / complications
  • Crohn Disease* / drug therapy
  • Female
  • Humans
  • Inflammatory Bowel Diseases / complications
  • Inflammatory Bowel Diseases / drug therapy
  • Male
  • Vancomycin* / therapeutic use

Substances

  • Vancomycin
  • Anti-Bacterial Agents